Go Blue
Our Clinical Trials

Pancreatic Cancer

NCT01196247: A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer.
(Questions / eligibility criteria! Click here)
SU2C PI: Ramesh Ramanathan, MD      TGen
Contact: (NOTE: Enrollment for this trial has been completed)
--
--



NCT01088815: Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas.
(Questions / eligibility criteria! Click here)
SU2C PI: Daniel Laheru, MD
Sidney Kimmel Comprehensive Cancer Center JHMI
Contact: Rosalind Walker, RN
410-955-9628
rwalker@jhmi.edu



NCT00844649: A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas.
(Questions / eligibility criteria! Click here)
SU2C PI: Daniel Von Hoff, MD
Translational Genomics Research Institute TGen
Contact: Amanda Johnson
919-433-8449
ajohnson@abraxisbio.com




NCT01506973:
A Phase I/II/Pharmacodynamic Study of Hydroxychloroquine in Combination With Gemcitabine/Abraxane to Inhibit Autophagy
in Pancreatic Cancer.
(Questions / eligibility criteria! Click here)
SU2C PI: Peter J. O’Dwyer, MD
University of Pennsylvania Cancer Center
Contact: Peter O'Dwyer, MD
215-662-2812
admin@ctsrmc.org